Literature DB >> 20150828

KCNH2 pharmacogenomics summary.

Connie Oshiro1, Caroline F Thorn, Dan M Roden, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20150828      PMCID： PMC3086352          DOI： 10.1097/FPC.0b013e3283349e9c

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  50 in total

Review 1.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.

Authors:  D M Roden; R Lazzara; M Rosen; P J Schwartz; J Towbin; G M Vincent
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

2.  Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.

Authors:  Ping Yang; Hideaki Kanki; Benoit Drolet; Tao Yang; Jian Wei; Prakash C Viswanathan; Stefan H Hohnloser; Wataru Shimizu; Peter J Schwartz; Marshall Stanton; Katherine T Murray; Kris Norris; Alfred L George; Dan M Roden
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

3.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

4.  Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.

Authors:  Zhuoqian Sun; Patrice M Milos; John F Thompson; David B Lloyd; Amy Mank-Seymour; Jodi Richmond; Jason S Cordes; Jun Zhou
Journal:  J Mol Cell Cardiol       Date:  2004-11       Impact factor: 5.000

5.  Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG).

Authors:  Kristian J Paavonen; Hugh Chapman; Päivi J Laitinen; Heidi Fodstad; Kirsi Piippo; Heikki Swan; Lauri Toivonen; Matti Viitasalo; Kimmo Kontula; Michael Pasternack
Journal:  Cardiovasc Res       Date:  2003-09-01       Impact factor: 10.787

Review 6.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

7.  Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation.

Authors:  Tomoko Sakaguchi; Hideki Itoh; Wei-Guang Ding; Keiko Tsuji; Iori Nagaoka; Yuko Oka; Takashi Ashihara; Makoto Ito; Yoshihiro Yumoto; Naoko Zenda; Yukei Higashi; Youichi Takeyama; Hiroshi Matsuura; Minoru Horie
Journal:  J Pharmacol Sci       Date:  2008-12-05       Impact factor: 3.337

Review 8.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

9.  Mechanisms of arsenic-induced prolongation of cardiac repolarization.

Authors:  Eckhard Ficker; Yuri A Kuryshev; Adrienne T Dennis; Carlos Obejero-Paz; Lu Wang; Peter Hawryluk; Barbara A Wible; Arthur M Brown
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

10.  Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.

Authors:  R S Duncan; M J McPate; J M Ridley; Z Gao; A F James; D J Leishman; J L Leaney; H J Witchel; J C Hancox
Journal:  Biochem Pharmacol       Date:  2007-05-03       Impact factor: 5.858
View more
  7 in total

1.  Pharmacogenomics and bioinformatics: PharmGKB.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

Review 2.  Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?

Authors:  Norman Stockbridge; Joel Morganroth; Rashmi R Shah; Christine Garnett
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

Review 3.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

4.  The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling.

Authors:  Gregory J Kaczorowski; Maria L Garcia; Jacob Bode; Stephen D Hess; Umesh A Patel
Journal:  Front Pharmacol       Date:  2011-12-13       Impact factor: 5.810

5.  Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines.

Authors:  A Chhibber; C E French; S W Yee; E R Gamazon; E Theusch; X Qin; A Webb; A C Papp; A Wang; C Q Simmons; A Konkashbaev; A S Chaudhry; K Mitchel; D Stryke; T E Ferrin; S T Weiss; D L Kroetz; W Sadee; D A Nickerson; R M Krauss; A L George; E G Schuetz; M W Medina; N J Cox; S E Scherer; K M Giacomini; S E Brenner
Journal:  Pharmacogenomics J       Date:  2016-02-09       Impact factor: 3.550

Review 6.  Pharmacogenomic Biomarkers and Their Applications in Psychiatry.

Authors:  Heejin Kam; Hotcherl Jeong
Journal:  Genes (Basel)       Date:  2020-11-30       Impact factor: 4.096

7.  The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.

Authors:  Fazhong He; Jianquan Luo; Zhiying Luo; Lan Fan; Yijing He; Dingliang Zhu; Jinping Gao; Sheng Deng; Yan Wang; Yuesheng Qian; Honghao Zhou; Xiaoping Chen; Wei Zhang
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.